<DOC>
	<DOC>NCT01588509</DOC>
	<brief_summary>This is a phase 1, randomized, open-label, parallel group study conducted in healthy postmenopausal women with low bone mineral density previously treated with alendronate.</brief_summary>
	<brief_title>Transition From Alendronate to AMG 785</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis, Postmenopausal</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Postmenopausal women, defined as no vaginal bleeding or spotting for ≥ 12 months Low bone mineral density at screening [defined by a bone mineral density (BMD) Tscore ≤ 2.0 and ≥ 4.0 at the lumbar spine (L1 to L4; or BMD Tscore of evaluable vertebrae), total hip, or femoral neck] Currently taking alendronate (70 mg weekly or equivalent) exclusively for ≥ 1 year with verbal agreement that the subject has taken ≥ 80% of their doses with good tolerance History of vertebral fracture, or fragility fracture of the wrist, humerus, hip or pelvis after age 50; or recent bone fracture within 6 months prior to screening History of metabolic or bone disease such as Paget's disease, rheumatoid arthritis, osteomalacia, osteogenesis imperfecta, osteopetrosis, ankylosing spondylitis, Cushing's disease, hyperprolactinemia, and malabsorption syndrome Vitamin D deficiency (defined as 25OHVitD levels &lt; 20 ng/mL)</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>AMG 785, bone mineral density, alendronate</keyword>
</DOC>